44 unchanged sentences
2 to the Amended and Restated Agreement, between the Company (formerly Inex Pharmaceuticals Corporation) and Hana Biosciences, Inc., effective as of September 20, 2010 (incorporated herein by reference to Exhibit 4.21 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 , filed with the SEC on June 3, 2011).
−Removed: 10.4**# Form of Arbutus Biopharma Corporation Indemnity Agreement.
+Added: 10.4*# Form of Arbutus Biopharma Corporation Indemnity Agreement (incorporated herein by reference to Exhibit 10.4 t o the R egistrant ’ s Annual Report on Form 10- K for the year ended December 31, 2022, filed with the SEC on March 3, 2022 ).
10.5†* License Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation executed on July 30, 2001 (incorporated herein by reference to Exhibit 4.17 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 , filed with the SEC on June 3, 2011).
28 unchanged sentences
and Roivant Sciences LTD.
−Removed: (incorporated herein by reference Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the Quarter ended March 31, 2018 filed with the SEC on May 4, 2018).
+Added: (incorporated herein by reference Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the q uarter ended March 31, 2018 , filed with the SEC on May 4, 2018).
10.22* Open Market Sale AgreementSM, dated December 20, 2018, by and between the Company and Jefferies LLC (incorporated herein by reference to Exhibit 1.1 of the Current Report on Form 8-K , filed with the SEC on December 20, 2018).
5 unchanged sentences
3 to the Open Market Sale AgreementSM, dated March 4, 2021, by and between Arbutus Biopharma Corporation and Jefferies LLC (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K , filed with the SEC on March 4, 2021.)
−Removed: 10.26*# Executive Employment Agreement, dated June 11, 2018, by and between the Company and David Hastings.
−Removed: (incorporated herein by reference to Exhibit 10.52 of the Form 10-K filed with the SEC on March 7, 2019).
−Removed: 10.27*# Executive Employment Agreement, dated October 8, 2018, by and between the Company and Gaston Picchio (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended September 30, 2018, filed with the SEC on November 7, 2018).
+Added: 10.26*# Executive Employment Agreement, dated June 11, 2018, by and between the Company and David Hastings (incorporated herein by reference to Exhibit 10.52 of the Registrant ’ s Annual Report on Form 10-K for the year end December 31, 2018 , filed with the SEC on March 7, 2019).
10.27*# Employment Agreement, dated June 13, 2019, by and between the Company and William H.
Collier (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K , filed with the SEC on June 18, 2019).
−Removed: 10.29*# Executive Employment Agreement, dated July 10, 2015, by and between the Company and Michael McElhaugh, as amended by the First Amendment to Executive Employment Agreement, dated April 20, 2016, and the Second Amendment to Executive Employment Agreement dated December 11, 2018 (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2019, filed with the SEC on August 5, 2019).
−Removed: 10.30* Purchase and Sale Agreement, dated July 2, 2019, by and between the Company and OCM IP Healthcare Portfolio LP (incorporated herein by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2019, filed with the SEC on August 5, 2019).
−Removed: 10.31*# Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented by the Committee on May 28, 2020 (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 1, 2020).
+Added: 10.28*# Executive Employment Agreement, dated July 10, 2015, by and between the Company and Michael McElhaugh, as amended by the First Amendment to Executive Employment Agreement, dated April 20, 2016, and the Second Amendment to Executive Employment Agreement dated December 11, 2018 (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q for the q uarter ended June 30, 2019, filed with the SEC on August 5, 2019).
+Added: 10.29* Purchase and Sale Agreement, dated July 2, 2019, by and between the Company and OCM IP Healthcare Portfolio LP (incorporated herein by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q for the q uarter ended June 30, 2019, filed with the SEC on August 5, 2019).
10.30*# Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K , filed with the SEC on June 1, 2020).
−Removed: 10.33*# Form of Arbutus Biopharma Corporation Option Agreement (incorporated herein by reference to Exhibit 10.8 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2019, filed with the SEC on August 5, 2019).
+Added: 10.31*# Form of Arbutus Biopharma Corporation Option Agreement (incorporated herein by reference to Exhibit 10.8 to the Registrant’s Quarterly Report on Form 10-Q for the q uarter ended June 30, 2019, filed with the SEC on August 5, 2019).
10.32*# Option Agreement, dated June 24, by and between the Company and William H.
−Removed: Collier (incorporated herein by reference to Exhibit 10.9 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2019, filed with the SEC on August 5, 2019).
−Removed: 10.35*# Offer Letter, dated August 8, 2019, by and between the Company and Andrew Cheng (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended September 30, 2019, filed with the SEC on November 6, 2019).
+Added: Collier (incorporated herein by reference to Exhibit 10.9 to the Registrant’s Quarterly Report on Form 10-Q for the q uarter ended June 30, 2019, filed with the SEC on August 5, 2019).
10.33†* Cross License Agreement, dated April 11, 2018, by and between the Company and Genevant Sciences Ltd.
−Removed: (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2020, filed with the SEC on August 7, 2020).
+Added: (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q for the q uarter ended June 30, 2020, filed with the SEC on August 7, 2020).
10.34†* First Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd and Genevant Sciences GmbH.
−Removed: (incorporated herein by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2020, filed with the SEC on August 7, 2020).
+Added: (incorporated herein by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q for the q uarter ended June 30, 2020, filed with the SEC on August 7, 2020).
10.35†* Second Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd.
and Genevant Sciences GmbH.
−Removed: (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2020, filed with the SEC on August 7, 2020).
+Added: (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q for the q uarter ended June 30, 2020, filed with the SEC on August 7, 2020).
10.36†* License Agreement, dated December 9, 2021, by and between the Company and Genevant Sciences GmbH (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K , filed with the SEC on December 10, 2021).
−Removed: 10.40* Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 1, 2021).
10.37†* Technology Transfer and Exclusive License Agreement, dated December 13, 2021, by and between the Company and Qilu Pharmaceutical Co., Ltd.
+Added: (incorporated herein by reference to Exhibit 10.41 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 3, 2022).
+Added: 10.38* Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K , filed with the SEC on May 31, 2022) .
+Added: 10.39*# Third Amendment to Executive Employment Agreement, dated November 1, 2022, by and between the Company and Michael McElhaugh (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K , filed with the SEC on October 24, 2022)
+Added: 10.41** Form of Arbutus Biopharma Corporation Restricted Stock Unit Agreement .
21.1** List of Subsidiaries.
24 unchanged sentences
ARBUTUS BIOPHARMA CORPORATION
−Removed: /s/ William Collier
−Removed: William Collier
+Added: /s/ William H.
President and Chief Executive Officer
15 unchanged sentences
Keith Manchester, M.D.
−Removed: /s/ Eric Venker, M.D., PharmD Director
−Removed: Eric Venker, M.D., PharmD
/s/ James Meyers Director
−Removed: /s/ Andrew Cheng, M.D., Ph.
−Removed: Andrew Cheng, M.D., Ph.
−Removed: /s/ Tram Tran, M.D.
−Removed: Tram Tran, M.D.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.